Table 6.
Author, year, country, and study type | Participants completed and dropouts | Measure | Preintervention Mean (SD) | Postintervention, Mean (SD) | P‐value | Follow‐up | Outcome |
---|---|---|---|---|---|---|---|
Oresland et al., 198851 Sweden Randomized controlled trial |
Training 18/20 Control 20/20 2 in training group withdrawn due to postoperative complication |
Maximum pouch volume Maximum anal resting and squeeze pressures Bowel frequency per 24 h —bowel diary Oresland functional score |
4 weeks after pouch construction 75ml Maximum resting pressure 50 mmHg Maximum squeeze pressure 170 mmHg 1 week after stoma closure Training group 7.3 (2.5) Control group 7.5 (2.5) Actual scores not stated |
Prior to stoma reversal Training group 136 (34) ml Control group 108 (57) ml 12 months after stoma closure Maximum volume both groups 265 ml At 12 months Maximum resting pressure Training group 56 (17) mmHg Control group 50 (15) mmHg Maximum squeeze pressure both groups = 200 mmHg 6 months after stoma closure Training group 4.9 (1.6) Control group 5.4 (1.8) Actual scores not stated |
NS NS NS NS NS NS |
Before stoma closure 1, 3, 6, and 12 months poststoma reversal |
Training prior to stoma reversal did not have a significant effect on maximum pouch volume, maximum anal squeeze pressure, or maximum anal resting pressure Training prior to stoma reversal did not affect functional outcome |
Jorge et al., 199452 USA Randomized controlled trial |
Training 13/13 Control 13/13 Dropouts not reported |
Anal sphincter pressures Cleveland Fecal Incontinence score |
Anal resting pressure Control 65 (15) mmHg Training 75 (25) mmHg Anal Squeeze pressure Control 128 (52) mmHg Training 97 (48) mmHg Control 0.2 (0.1)Training 0.2 (1.2) |
Anal resting pressure Control 44 (14) mmHg Training 48 (18) mmHg Anal Squeeze pressure Control 110 (48) mmHg Training 86 (44) mmHg Control 2.8 (1.6) Training 2.0 (1.2) |
0.20 0.300.07 |
Within 1 month of stoma reversal | Training prior to stoma reversal did not affect anal pressures or functional outcome soon after stoma reversal |
Hull et al.,199553 USA Prospective case series |
12/13 1 patient was lost to follow‐up |
Patient report of symptom resolution and normal EMG | None reported | None reported | Not reported |
Average follow‐up 8 months Range, 1–15 |
Improved 9/12 (75%) No change 2/12 (17%) All 11 normalized EMG |
Quinn et al., 201739 USA Retrospective case series |
22/33 7 dropped out due to pain with treatment 3 with time constraints 1 due to lack of progress |
Patient rating 15‐point Likert scale −7 “a great deal worse” 0 “no change” + 7 “a very great deal better” Physician rating of improvement “significant improvement” “mild–moderate improvement” “no change” |
Not reported |
Change in patient rating scale +4.6 |
Not reported | At completion of training |
Significant improvement 5/22 (23%) Mild–moderate improvement 15/22 (68%) No change 2/22 (9%) |
Segal et al., 201855 UK Retrospective case series |
24/24 Objective data available for only 9/24 patients |
Subjective improvement rating by 2 independent reviewers from patient reports in the medical record ICIQ‐B questionnaire Bowel pattern Bowel control Nonscored Quality of life St Marks tool for ED |
Not relevant FI Group n = 5/16 Median (range)62 (49–62) 82 (33–102) 22 (17–35) 80 (62–98) ED Group n = 4/8 Incomplete emptying 4/4 (100%) Straining 4/4 (100%) Pain 4/4 (100%) Bloating 3/4 (75%) Laxatives 1/4 (25%) |
Not reported 46 (39–62) 53 (11–76) 29 (12–29) 41 (30–55) Incomplete emptying 4/4 (100%) Straining 2/4 (50%) Pain 1/4 (25%) Bloating 2/4 (50%) Laxatives 0/4 (0%) |
Not reported 0.12 0.21 0.35 0.01 * Not reported |
Median follow‐up 3 months from last biofeedback session Range, 1–6 months |
FI Much improved 4/16 25% Some improvement 8/16 50% No improvement 4/16 25% ED Much improved 4/8 50% Some improvement 2/8 25% No improvement 2/8 25% Combined outcome (FI and ED) Improved 75% |
P < 0.05.
ED, evacuation disorder; EMG, electromyography; FI, fecal incontinence; ICIQ, International Consultation on Incontinence questionnaire‐bowel; NS, not significant.